Solnick Rachel E, Patel Rahi, Chang Ethan, Vargas-Torres Carmen, Munawar Maaz, Pendell Carlin, Smith Judith E, Cowan Ethan, Kocher Keith E, Merchant Roland C
medRxiv. 2024 Aug 20:2024.08.20.24312317. doi: 10.1101/2024.08.20.24312317.
In US emergency departments (EDs), empiric antibiotic treatment for gonorrhea (GC) and chlamydia (CT) is common due to the unavailability of immediate test results. Evidence suggests sex-based disparities in treatment practices, with females potentially receiving less empiric treatment than males.
To investigate sex differences in empiric antibiotic treatment for GC and CT in EDs, comparing practices to subsequent laboratory-confirmed results.
This systematic review and meta-analysis included studies from US EDs reporting GC/CT testing and empiric antibiotic treatment from January 2010 to February 2021. A total of 1,644 articles were screened, with 17 studies (n = 31,062 patients) meeting inclusion criteria.
The primary outcomes were GC/CT test positivity, empiric antibiotic treatment rates, and discordance between treatment and test results, stratified by sex. Data were analyzed using a random-effects model.
Overall GC/CT positivity was 14% (95% CI, 11%-16%): 11% (95% CI, 8%-14%) in females and 25% (95% CI, 23%-26%) in males. Empiric antibiotic treatment was administered in 46% (95% CI, 38%-55%) of cases: 31% (95% CI, 24%-37%) in females and 73% (95% CI, 65%-80%) in males. Among patients without a laboratory-confirmed infection, 38% (95% CI, 30%-47%) received treatment: 27% (95% CI, 20%-34%) of females and 64% (95% CI, 55%-73%) of males. Conversely, 39% (95% CI, 31%-48%) of patients with laboratory-confirmed infections were not treated: 52% (95% CI, 46%-57%) of females and 15% (95% CI, 12%-17%) of males.
There is significant discordance between ED empiric antibiotic treatment and laboratory-confirmed results, with notable sex-based disparities. Females were 3.5 times more likely than males to miss treatment despite confirmed infection. These findings highlight the need for improved strategies to reduce sex-based disparities and enhance empiric treatment accuracy for GC/CT in ED settings.
Are there sex-based differences in empiric antibiotic treatment for gonorrhea and chlamydia in US emergency departments (EDs), and how do these practices compare to laboratory-confirmed results? In this systematic review and meta-analysis of 17 studies with 31,062 patients, females were significantly less likely than males to receive empiric antibiotic treatment for gonorrhea and chlamydia. Additionally, 39% of patients with a laboratory-confirmed infection were not empirically treated, with females 3.5 times more likely to miss treatment than males. The findings indicate significant sex disparities in ED empiric antibiotic treatment for sexually transmitted infections, underscoring the need for improved strategies to ensure equitable and accurate treatment across sexes.
在美国急诊科(EDs),由于无法即时获得检测结果,对淋病(GC)和衣原体(CT)进行经验性抗生素治疗很常见。有证据表明治疗方法存在性别差异,女性可能比男性接受的经验性治疗更少。
调查急诊科对GC和CT进行经验性抗生素治疗的性别差异,并将治疗方法与后续实验室确诊结果进行比较。
设计、背景和参与者:这项系统评价和荟萃分析纳入了来自美国急诊科的研究,这些研究报告了2010年1月至2021年2月期间的GC/CT检测和经验性抗生素治疗情况。共筛选了1644篇文章,17项研究(n = 31062例患者)符合纳入标准。
主要结局为GC/CT检测阳性率、经验性抗生素治疗率以及治疗与检测结果之间的不一致性,按性别分层。数据采用随机效应模型进行分析。
总体GC/CT阳性率为14%(95%CI,11% - 16%):女性为11%(95%CI,8% - 14%),男性为25%(95%CI,23% - 26%)。46%(95%CI,38% - 55%)的病例接受了经验性抗生素治疗:女性为31%(95%CI,24% - 37%),男性为73%(95%CI,65% - 80%)。在未得到实验室确诊感染的患者中,38%(95%CI,30% - 47%)接受了治疗:女性为27%(95%CI,20% - 34%),男性为64%(95%CI,55% - 73%)。相反,39%(95%CI,31% - 48%)实验室确诊感染的患者未接受治疗:女性为52%(95%CI,46% - 57%),男性为15%(95%CI,12% - 17%)。
急诊科经验性抗生素治疗与实验室确诊结果之间存在显著不一致,且存在明显的性别差异。尽管确诊感染,女性错过治疗的可能性是男性的3.5倍。这些发现凸显了需要改进策略以减少性别差异,并提高急诊科对GC/CT经验性治疗的准确性。
在美国急诊科,淋病和衣原体经验性抗生素治疗存在性别差异吗?这些治疗方法与实验室确诊结果相比如何?在这项对17项研究、31062例患者的系统评价和荟萃分析中,女性接受淋病和衣原体经验性抗生素治疗的可能性明显低于男性。此外,39%实验室确诊感染的患者未接受经验性治疗,女性错过治疗的可能性是男性的3.5倍。研究结果表明急诊科对性传播感染的经验性抗生素治疗存在显著性别差异,强调需要改进策略以确保两性获得公平、准确的治疗。